Acrux Limited (ASX: ACR)
Health Care · Pharmaceuticals · AU
AU$0.01
-9.09% today · -33.3% 1Y
Acrux Limited (ASX: ACR) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.23M and employs 43 people.
Over the last twelve months the share price has lost 33.3%, trading between 0.01 and 0.02.
Tweenvest scores Acrux Limited across four factors: quality 24/100, value 53/100, growth 0/100. Its strongest factor is value.
ACR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.23M
- Revenue (TTM)
- $1.87M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.97
- 52-week high
- AU$0.02
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 589.68M
- Employees
- 43
- Next earnings
- —
About Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
- ISIN
- AU000000ACR3
- Founded
- 1998
- Listed since
- Sep 29, 2004
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.50 | -0.03% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.54 | -0.55% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.87 | +0.14% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.04 | +0.25% |
Figures last refreshed Aug 18, 2026.